Please login to the form below

Not currently logged in
Email:
Password:

Step forward in cancer research

Scientists have found some 'junk DNA' sequences have important roles in the genome that could help diagnose breast and bowel cancer

Scientists have found that a group of rogue genetic messengers, produced by DNA sequences commonly known as 'junk DNA', could help diagnose breast and bowel cancer.

The researchers, funded by Cancer Research UK and led by Dr Cristina Tufarelli at the University of Nottingham, discovered that seven of these faulty genetic messengers - known as chimeric transcripts - are more common in breast cancer cells. Five were only present in breast cancer cells, while two were found in both normal and breast cancer cells.

These rogue messengers are produced by DNA sequences called LINE-1 (L1). Despite being labelled as 'junk DNA' it is clear that some of these sequences have important roles in the genome, such as influencing when genes are switched on.

L1s carry a switch that can randomly turn on nearby genes. When this occurs, they make the rogue genetic messengers that can sabotage the normal functioning of cells. To prevent the potentially damaging effects of these rogue elements, normal cells silence L1s with a chemical 'off switch'.

In cancerous cells this 'off switch' is often missing, leading to the production of rogue genetic messengers.

Dr Tufarelli said: "This study has generated new research tools to investigate the role of 'junk DNA' in cancer development. The next step is to find out if the switching on of these genes is driving cancer or if they are a result of the cancer. Even if they are innocent bystanders of cancer, they could be useful biomarkers helping us to diagnose or monitor the disease."

The researchers extended their studies to look at two bowel cancer cell lines. Two of the rogue messengers were only found in invasive bowel cancer cell lines, suggesting that these sequences could play a role in cancer progression.

Dr Tufarelli added: "If this 'junk DNA' does turn out to play a role in cancer then we could be at the tip of the iceberg in understanding a completely new mechanism behind the disease. If we do find out that they are playing a role then they could be useful targets for new treatments."

The research has been published in the journal Genomics.
 

6th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics